CCR5 and myeloid sarcoma: Although meta-analyses of published studies have found no association between the CCR5 Δ32 and CTLA-4 +49 A/G polymorphisms and susceptibility to MS in Europeans [14,15] their influence on clinical expression or the response to treatment cannot be ruled out, especially if they are combined or considered together.